Joinn Laboratories (China) Co (SHSE:603127) Risk Assessment

View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Joinn Laboratories (China) Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Joinn Laboratories (China) Co's Risk Assessment

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Joinn Laboratories (China) Co's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Risk Assessment falls into.

Joinn Laboratories (China) Co (SHSE:603127) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Joinn Laboratories (China) Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (SHSE:603127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

06127:Hong Kong

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Yao Da Lin	Director
Sun Yun Xia	Director
Zuo Cong Lin	Director
Gao Da Peng	Director
Li Ye	Supervisors
Gu Xiao Lei	Director
Feng Yu Xia	Director
Gu Jing Liang	senior management
Yu Ai Shui	senior management
Yin Li Li	Supervisors
Sun Hui Ye	Supervisors
Gu Mei Fang	Director

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines